Abstract
Abstract
Purpose
Tumour perfusion is a nutrient-agnostic biomarker for cancer metabolic rate. Use of tumour perfusion for cancer growth assessment has been limited by complicated image acquisition, image analysis and limited field-of-view scanners. Long axial field-of-view (LAFOV) PET scan using [15O]H2O, allows quantitative assessment of whole-body tumour perfusion. We created a tool for automated creation of quantitative parametric whole-body tumour perfusion images in metastatic cancer.
Methods
Ten metastatic prostate cancer patients underwent dynamic LAFOV [15O]H2O PET (Siemens, Quadra) followed by [18F]PSMA-1007 PET. Perfusion was measured as [15O]H2O K1 (mL/min/mL) with a single-tissue compartment model and an automatically captured cardiac image-derived input function. Parametric perfusion images were automatically calculated using the basis-function method with initial voxel-wise delay estimation and a leading-edge approach. Subsequently, perfusion of volumes-of-interest (VOI) can be directly extracted from the parametric images. We used a [18F]PSMA-1007 SUV 4 fixed threshold for tumour delineation and transferred these VOIs to the perfusion map.
Results
For 8 primary tumours, 64 lymph node metastases, and 85 bone metastases, median tumour perfusion were 0.19 (0.15–0.27) mL/min/mL, 0.16 (0.13–0.27) mL/min/mL, and 0.26 (0.21–0.39), respectively. The correlation between calculated perfusion from time-activity-curves and parametric images was excellent (r = 0.99, p < 0.0001).
Conclusion
LAFOV PET imaging using [15O]H2O enables truly quantitative parametric images of whole-body tumour perfusion, a potential biomarker for guiding personalized treatment and monitoring treatment response.
Funder
Tømrermester Jørgen Holm og hustru Elisa f. Hansens Mindelegat
NEYE-Fonden
P. A. Messerschmidt og Hustrus Fond
Fabrikant Einar Willumsens Mindelegat
Else og Mogens Wedell Wedellsborgs Fond
Novo Nordisk Fonden
Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70.
2. Johnson GB, Harms HJ, Johnson DR, Jacobson MS. PET imaging of Tumor Perfusion: a potential Cancer biomarker? Seminars in nuclear medicine. 2020;50(6):549–61. https://doi.org/10.1053/j.semnuclmed.2020.07.001.
3. Kurdziel KA, Figg WD, Carrasquillo JA, Huebsch S, Whatley M, Sellers D, et al. Using positron emission tomography 2-deoxy-2-[18F]fluoro-D-glucose, 11CO, and 15O-water for monitoring androgen independent prostate cancer. Mol Imaging Biology: MIB : Official Publication Acad Mol Imaging. 2003;5(2):86–93.
4. Inaba T. Quantitative measurements of prostatic blood flow and blood volume by positron emission tomography. J Urol. 1992;148(5):1457–60.
5. Tolbod LP, Nielsen MM, Pedersen BG, Hoyer S, Harms HJ, Borre M, et al. Non-invasive quantification of tumor blood flow in prostate cancer using (15)O-H2O PET/CT. Am J Nucl Med Mol Imaging. 2018;8(5):292–302.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献